Cardax Inc
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and w… Read more
Cardax Inc (CDXI) - Net Assets
Latest net assets as of March 2021: $-11.35 Million USD
Based on the latest financial reports, Cardax Inc (CDXI) has net assets worth $-11.35 Million USD as of March 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.38 Million) and total liabilities ($12.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-11.35 Million |
| % of Total Assets | -823.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cardax Inc - Net Assets Trend (2011–2020)
This chart illustrates how Cardax Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cardax Inc (2011–2020)
The table below shows the annual net assets of Cardax Inc from 2011 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | $-10.20 Million | -41.66% |
| 2019-12-31 | $-7.20 Million | -103.62% |
| 2018-12-31 | $-3.54 Million | -151.54% |
| 2017-12-31 | $-1.41 Million | +63.83% |
| 2016-12-31 | $-3.89 Million | -3.67% |
| 2015-12-31 | $-3.75 Million | -16.60% |
| 2014-12-31 | $-3.21 Million | +75.15% |
| 2013-12-31 | $-12.94 Million | -145265.91% |
| 2012-12-31 | $-8.90K | -115.82% |
| 2011-12-31 | $56.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cardax Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7209186200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $794.00 | % |
| Other Components | $61.89 Million | % |
| Total Equity | $-10.20 Million | 100.00% |
Cardax Inc Competitors by Market Cap
The table below lists competitors of Cardax Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Araneta Properties Inc
PSE:ARA
|
$59.09 |
|
Caduceus Software Systems Corp
PINK:CSOC
|
$59.16 |
|
Alternaturals Inc
PINK:ANAS
|
$59.19 |
|
British Smaller Companies Vct 2 Plc
LSE:BSC
|
$59.25 |
|
City and Land Developers Inc
PSE:LAND
|
$58.76 |
|
Humble Energy Inc
PINK:HUML
|
$58.66 |
|
O.A.T. Inc
PINK:OATN
|
$58.55 |
|
China Intel Info Sys
PINK:IICN
|
$58.46 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cardax Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from -7,198,849 to -10,197,996, a change of -2,999,147.
- Net loss of 5,055,507 reduced equity.
- Other factors increased equity by 2,056,360.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.06 Million | -49.57% |
| Other Changes | $2.06 Million | +20.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cardax Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.25 | $0.00 | x |
| 2012-12-31 | $-0.04 | $0.00 | x |
| 2013-12-31 | $-1.36 | $0.00 | x |
| 2014-12-31 | $-10.67 | $0.00 | x |
| 2015-12-31 | $-11.21 | $0.00 | x |
| 2016-12-31 | $-10.19 | $0.00 | x |
| 2017-12-31 | $-2.81 | $0.00 | x |
| 2018-12-31 | $-5.55 | $0.00 | x |
| 2019-12-31 | $-10.58 | $0.00 | x |
| 2020-12-31 | $-13.70 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cardax Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -938.04%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-1.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -17.30% | -13.39% | 1.23x | 1.05x | $-15.36K |
| 2012 | 0.00% | -86.47% | 6.05x | 0.00x | $-64.27K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.84 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.67 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.88 Million |
| 2016 | 0.00% | -5059.01% | 0.05x | 0.00x | $-1.40 Million |
| 2017 | 0.00% | -325.28% | 0.19x | 0.00x | $-1.84 Million |
| 2018 | 0.00% | -266.35% | 0.61x | 0.00x | $-3.67 Million |
| 2019 | 0.00% | -716.37% | 0.35x | 0.00x | $-4.37 Million |
| 2020 | 0.00% | -938.04% | 0.38x | 0.00x | $-4.04 Million |
Industry Comparison
This section compares Cardax Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cardax Inc (CDXI) | $-11.35 Million | -17.30% | N/A | $59.02 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |